Diplomat Pharmacy, Inc. (DPLO): Price and Financial Metrics
DPLO Stock Summary
- NA's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 99.4% of US listed stocks.
- DPLO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.02 -- higher than merely 0.64% of US-listed equities with positive expected earnings growth.
- In terms of twelve month growth in earnings before interest and taxes, NA is reporting a growth rate of -2,110.81%; that's higher than merely 0.74% of US stocks.
- Stocks that are quantitatively similar to DPLO, based on their financial statements, market capitalization, and price volatility, are NCSM, CIR, AFH, SMIT, and TSRI.
DPLO Stock Price Chart More Charts
DPLO Price/Volume Stats
|Current price||$4.00||52-week high||$14.46|
|Prev. close||$3.99||52-week low||$2.43|
|Day high||$4.01||Avg. volume||795,738|
|50-day MA||$4.18||Dividend yield||N/A|
|200-day MA||$5.01||Market Cap||304.00M|
Diplomat Pharmacy, Inc. (DPLO) Company Bio
Diplomat Pharmacy operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company was founded in 1975 and is focused in Flint, Michigan.